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Classic Kaposi sarcoma (KS) is a rare human herpes virus 
8-associated angioproliferative disease, and the dissem-
inated classic type of KS in Korea is even rarer. The treatment 
options for classic KS vary and range from surgical excision 
to ionizing irradiation or chemotherapy. Recently, there 
have been a few reports of treating classic KS with paclitaxel, 
which has been used to treat AIDS-associated KS and 
post-transplant KS. We herein report a case of disseminated 
classic type KS in a 78-year-old Korean male patient who 
showed dramatic response after only two cycles of paclitaxel 




Kaposi’s sarcoma (KS) is rare type of visceral and soft 
tissue sarcoma related to human herpes virus (HHV)-8 that 
usually occurs in elderly men
1. It is characterized by the 
proliferation of spindle shaped cells, mainly of vascular 
origin. Proliferation of those cells is considered to be the 
neoplastic elements of KS, along with neoangiogenesis, 
inflammatory cell infiltration and edema
2. Among the four 
types of KS, treatment of the classic type KS varies, 
depending on the progression of disease and age of the 
patients
3,4. Usually, localized classic type KS is effectively 
treated by radiotherapy or surgery, but disseminated classic 
type KS is treated by controversial methods such as 
radiotherapy, chemotherapy, and immunomodulatory agents
5. 
Taxanes (paclitaxel or docetaxel) have been used for the 
treatment of various tumors, including ovarian, breast, and 
lung carcinomas
6. Moreover, several studies have shown 
that paclitaxel monotherapy is a successful second-line 
treatment for both AIDS-associated KS
7 and KS in a 
therapeutically immunosuppressed patient
8. Reports about 
the clinical efficacy of taxanes (paclitaxel or docetaxel) are 
anecdotal, and treatment of disseminated classic KS with 
paclitaxel in Korea is very rare. Below, we report a patient 
with disseminated classic type KS who showed a dramatic 
response to paclitaxel therapy.
CASE REPORT
A 78-year-old man had developed a purpuric plaque on 
his left thumb 7-month ago. Progressive spreading vio-
laceous plaques with dark purple disseminated nodules 
appeared on his extremities, and lymphedematous change 
was noted on the left arm (Fig. 1A). He had no history of 
trauma to the left thumb or treatment history with 
corticosteroids or anticoagulation drugs.
The biopsy of his arm disclosed no specific change in the 
epidermis, but the whole dermis was composed of 
extensive hemorrhaging and the presence of irregular 
anastomosing vascular channels lined by atypical, enlarged 
endothelial cells permeated by collagen bundles. Immuno-Treatment of Disseminated Classic Type of Kaposi’s Sarcoma with Paclitaxel
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Fig. 1. (A) Clinical appearance before treatment with paclitaxel. Multiple reddish-purple plaques and patches with pitting edema 
distributed widely on upper and lower extremities. (B) Residual hyperpigmented patches after 2 infusions of paclitaxel. Note the edema
has all resolved and nearly skin lesions are disappeared.
Fig. 2. (A) Skin biopsy specimen showing infiltrate of spindles 
shaped cells and slit-like vascular spaces containing erythrocytes
in Kaposi’s sarcoma (H&E stain, ×200). (B) CD31 stain showing
positive reaction to well-formed flattened endothelial cell lining 
the vascular cleft and spindle-shaped stromal cells (×200). (C) 
CD34 stain showing prominent positive reaction in the spindle 
cell  population (×200).
histochemical staining for CD 31 and CD 34 were positive 
in the endothelial cells and the spindle-shaped cells in the 
dermis (Fig. 2). The clinical and pathologic features 
indicated that the diagnosis was consistent with KS.
Laboratory tests for the human immunodeficiency virus or 
immunosuppression were all negative. Computed tomo-
graphy scans of the neck, chest and abdomen revealed no 
metastatic lesions, and the brain magnetic resonance 
imaging revealed no evidence of metastasis. At multi-
disciplinary review, we planned paclitaxel monotherapy, 
which has been proved to be effective and well tolerated 
in patients with aggressive refractory classic KS, because 
the patient was elderly. We chose paclitaxel (Genexol-PM; 
Samyang, Seoul, Korea) as a monotherapy to reduce 
complications and improve the quality of life. Paclitaxel 
was administered intravenously at a dose of 135 mg/m
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once every three weeks. After two infusions, the KS 
lesions showed dramatic improvement, with improvement 
of the hyperpigmentation and edema in the extremities 
(Fig. 1B). Though the patient required additional treat-
ment, we could not continue the paclitaxel because of his 
old age and poor general condition. During the six-month 




The pathogenesis of KS is multifactorial, including HHV8, 
inflammatory cytokines, basic fibroblast growth factor, 
vascular endothelial growth factor, the proteins encoded 
by the HHV8 latency genes, matrix metalloproteinases, 
oncogenes, and oncosuppressor genes that induce 
initiation and/or progression
3. There are four variant 
clinical and epidemiological forms of KS that have been 
recognized: Classic KS or Mediterranean KS, Endemic KS 
or African KS, KS in therapeutically immunosuppressed 
patients, and AIDS associated KS (AIDS-KS). 
Classic KS is an uncommon disease among middle aged 
and elderly men of Mediterranean or Jewish lineage
9,10. In 
Korea, Classic KS occurrences are rare, especially the 
disseminated classic type of KS. Classic KS usually starts to 
appear on the skin of the lower extremities, where it is 
frequently misdiagnosed as a bruise. As time progresses, 
the lesions increase in size and number, and the color gets 
darker. Early diagnosis is paramount to decrease meta-
stasis to other organ systems such as the lungs, kidneys, 
and liver
11.
Therapeutic options for KS are based upon disease stage, 
progression pattern and distribution, clinical type, and 
immune status
12,13. For KS patients with more widely 
disseminated, progressive or symptomatic disease, sys-
temic therapy with cytotoxic chemotherapy is generally 
warranted
14. Vinblastine and bleomycin or vinblastine 
alone can be considered to be first-line therapy in Classic 
KS
15. Those regimens have shown promising results in 
patients with severely compromised immune function 
(leucopenia and neutropenia are quite frequent). Other 
systemic medications that are Food and Drug Admi-
nistration approved are liposomal doxorubicin, paclitaxel, 
and interferon-α
16. However, since liposomal doxorubicin 
was not available in Korea, and interferon-α caused 
immediate toxicity (chills, fever and malaise), those 
therapies were not chosen for this study. Paclitaxel has a 
powerful anti-tumor effect, used in the treatment of several 
carcinomas arising from the ovary, breast, and lungs. 
Paclitaxel actively impact the microtubules and cellular 
vital processes in non-mitotic phases of the cell cycle and 
inhibits the growth of either rapidly or slowly proliferating 
tumors
17. Paclitaxel has also been used successfully in 
AIDS-associated KS victims who failed to previously 
respond to systemic chemotherapy. 
There have been some anecdotal reports on the efficacy of 
paclitaxel in non-HIV-associated forms of KS, and, only 
recently, there was a report about the tolerability and 
clinical efficacy of paclitaxel in a homogeneous group of 
advanced aggressive classic KS
15,18. The protocol of the 
above-mentioned studies differs from this study. The 
results of paclitaxel in those studies were analogous to our 
study, however, and our patient showed rapid response 
after two cycles. Although we had to end the treatment 
after two cycles, the results are still significant considering 
the age of the patient.
We suggest a first line, short-term therapy in seriously 
invalid patients as well as a second line therapy after IFN 
α and/or vinblastine failure. Further studies are required to 
standardize the paclitaxel treatment schedule and dosage 
in the disseminated classic type of KS.
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